Nifty may open down, but strength seen at lower levels
April 23, 2021
Privi Speciality, Glnnd Pharma, Tata Motors scrips likely to see action today Rising Covid cases are likely keep Indian markets in a bear grip on Friday even as global markets present mixed cues. The US markets slumped almost one per cent overnight on fears of imposition of new capital gains tax by Joe Biden administration.
SGX Nifty at 14,331 indicates a gap-down opening of 70 points for Nifty futures, which closed at 14,403 on Thursday. The SGX Nifty futures recovered from the day s low of 14,260, signalling some value buying happening at lower levels.
Read more about Sensex drops below 48,000 amid volatility; breadth strong on Business Standard. Key benchmark indices are trading lower in early trade on selling pressure in index pivotals. At 9:25 IST, the barometer index, the S&P BSE Sensex, was down 208.94 points or 0.43% at 47,871.73. The Nifty 50 index was down 51.85 points or 0.36% at
Read more about Tata Motors, Indus Towers, Tata Elxsi in focus on Business Standard. Tata Motors said that the company s wholly owned subsidiary - Jaguar Land Rover UK, like other automotive manufacturers, is currently experiencing some Covid-19 supply chain disruption, including the global availability of semi-conductors, which is
Gland Pharma received approval from the United States Food and Drug Administration (US FDA) for generic Foscarnet Sodium Injection, 6000 mg/250 mL (24 mg/mL) Single-Dose Bag for Infusion.
Generic Foscarnet Sodium Injection is the bioequivalent and therapeutically equivalent to the Reference Listed Drug (RLD), Foscavir Injection, 24 mg/mL, of Clinigen Healthcare.
With this approval, Gland Pharma secured the first generic offering status in Single-Dose Bag for Infusion. Gland Pharma is backward integrated with in-house API source for this product. Gland Pharma intends to supply this product globally and recently launched the product in the Canadian market. Global markets size is estimated to be $50 million.
Par
Used to treat chronic idiopathic constipation, as well as opioid-induced constipation in adult with chronic non-cancer pain, including patients with chronic pain related to prior cancer or its treatment who do not require frequent (eg, weekly) opioid dosage escalation. The drug is also used to treat irritable bowel syndrome with constipation in women at least 18 years old
1/4/2021